The synergies and discord between holding both innovative and generics businesses, the most optimum allocation of capital and differing tax implications form the core of Novartis’ current thinking around its plans to conduct a strategic review of its $10bn Sandoz generics and biosimilars business, including for a potential divestment.
Novartis Weighs Synergies, Spending And Tax Under Sandoz Review
‘We Believe The Generics Market Is Attractive,’ Novartis Says
Novartis gave further color during its Q3 earnings call on its plans to conduct a strategic review for its Sandoz business. The Street also had its say, following years of calls by investors for Novartis to weigh Sandoz’ future as part of the group.
More from Business
• By
Amneal has spoken excitedly about its Crexont (carbidopa/levodopa) extended-release capsules as the Parkinson’s disease drug passes six months on the market.
• By
Sandoz CEO Richard Saynor has spoken of his frustration at a lawsuit from J&J seeking to prevent the launch of a private-label ustekinumab biosimilar in the US, which he described as “the desperate actions of an originator trying to protect its market.”
• By
Sandoz passed a major milestone in 2024, with the firm’s sales for the first time exceeding $10bn on the back of a significant rise in biosimilars turnover. The company is continuing to push ahead with restructuring initiatives and also addressed the potential threat of US tariffs as management discussed the firm’s annual results.
• By
Amgen has confirmed to Generics Bulletin details of its launch of Bkemv, the first US biosimilar to Soliris.
More from Generics Bulletin
• By
2025 is likely to be a game-changing year for the pharmaceutical industry. Generics Bulletin sat down with Medicines for Europe’s Adrian van den Hoven and Beata Stepniewska to discuss the opportunities of the Critical Medicines Act and EU pharmaceutical legislation revision.
• By
In a wide-ranging conversation, the AAM’s president and CEO John Murphy talks to Generics Bulletin about how the US industry association is planning to gain traction with the new Trump administration by adopting “a much more aggressive communications approach” on topics including medicines shortages, trade tariffs, PBM reform, the IRA and biosimilar interchangeability.
• By
Amgen has confirmed to Generics Bulletin details of its launch of Bkemv, the first US biosimilar to Soliris.